FDA Clears Ravulizumab for Atypical Hemolytic Uremic Syndrome

Share this post

At 26 weeks, complete thrombotic microangiopathy (TMA) response was achieved in 54% of adults and 71% of children treated with the long-acting C5 complement inhibitor.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply